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June 2, 2004:2147–51iterature, but then to perform a small validation study before
dopting a new technique with confidence.
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herapy of Recurrent Pericarditis
e read with interest the paper by Raatikka et al. (1) that gives us
useful piece of information regarding pericarditis in children.
he data are relevant, particularly regarding the good long-term
utcome, with no instance of constriction, in agreement with our
xperience in adults. We would like to comment on some
tatements regarding therapy. The authors in fact conclude that
orticosteroids, methotrexate, azathioprine, cyclosporine, and col-
hicine did not prevent recurrences. Should we conclude that no
rug is effective, so that no drug should be employed? We have
ublished case reports describing different experiences. A 14.5-
ear-old boy (2) previously treated with high-dose steroids, intra-
enous immunoglobulin, and indomethacin experienced an excel-
ent response when colchicine 1 mg was added, while slowly
apering steroids and continuing indomethacin. In another 12-
ear-old boy (3) who did not respond well to nonsteroidal
nti-inflammatory drugs (NSAIDs) and prednisone, the introduc-
ion of colchicine proved beneficial; thereafter, the patient pre-
ented with six relapses, each occurring 1 to 4 weeks after the
iscontinuation of colchicine on his own initiative. The excellent
tudy by Raatikka et al. (1), in our opinion, was not designed to
ssess the problem of therapy, with the interactions between
ifferent drugs, dosages, and combinations: we have to wait for
ore definitive studies specifically addressing therapy. Moreover,
e have to evaluate if efficacy of a drug means that it must work
fter discontinuing all the previous therapies (e.g., to stop steroids
nd NSAIDs and add de novo colchicine) or, probably more
isely, if a drug’s efficacy means that it works when added to a
revious active therapy (e.g., to add colchicine to steroids and
SAIDs).
In the meantime, even if it will be proved true that recurrent
ericarditis has a chronic course irrespective of the therapy given,
nd that the activity of the disease gradually “burns out” sponta-
eously, it remains necessary to use some drugs, the less toxic ones,
uring the acute phases. In our opinion, this is best accomplished mith a multidrug therapy including: 1) a very slow tapering of
teroids (months), similar to what is often done in many rheuma-
ologic conditions; 2) NSAIDs used at the recommended dosages;
nd 3) introduction of colchicine, if tolerated. In our experience,
his therapy greatly ameliorates the quality of life of these patients,
nd possibly may reduce the number of recurrences. We acknowl-
dge that it will be difficult to formally prove the efficacy of this
herapy in the framework of a randomized, controlled trial.
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EPLY
e appreciate the interest of Dr. Brucato and his colleagues in our
tudy on recurrent pericarditis in children and adolescents (1). We
gree that the treatment of this condition is often problematic and
rustrating. The goals of the therapy are to control the pain, to
revent tamponade, and to stop recurrences. In our series, threat-
ning tamponade was not encountered after first attacks and
ericardial effusion diminished in later relapses irrespective of the
iven therapy. Thus, the control of pain remains the main task in
herapy during a recurrence of the disease. This is possible in most
ases with nonsteroidal anti-inflammatory drugs (NSAIDs) in
ufficient doses, added with other pain killers if needed. Even
ecurrences with high C-reactive protein values usually settle down
ith such treatment within 7 to 10 days. It is tempting to use
orticosteroids as they are very effective in suppressing the pain and
n relieving the pericardial effusion. However, in our patients
teroid treatment tended to increase the number of relapses.
urther, the well-known side effects of corticosteroids are espe-
ially undesirable in growing children and adolescents. Therefore,
e would spare the corticosteroid treatment for the most severe
ases only.
Colchicine treatment for preventing relapses has raised consid-
rable expectations because of the good results published by Adler
t al. (2). Sadly, this treatment failed to prevent recurrences in all
our of our patients in whom colchicine was added to corticoste-
oid treatment. One possible reason for the contradicting results
ay lie in the different genetic characteristics of the study
